As of November 2024, more than 400,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,200,000 patient years1
>9,900 patients in clinical trials and open-label extensions
>391,000 patients with post-marketing experience
As of November 2024, more than 400,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,200,000 patient years1
>9,900 patients in clinical trials and open-label extensions
>391,000 patients with post-marketing experience
References
1. Roche data on file: clinical trials data cut-off Mar 2024 and post-marketing experience data cut-off Nov 2024